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Jose A. Ramirez, MD, William D. Suggs, MD, Richard E. Parsons, MD, 
Luis A. Sanchez, MD, and Ross T. Lyon, MD, New York, N.Y. 
Purpose: Vein graft stenosis caused by intimal hyperplasia (IH) accounts for 30% to 50% of 
late bypass graft failures; however, the biochemical mediators of vein graft IH have been 
poorly defined. We attempted to evaluate the spatial and temporal distribution of five 
principal cytokines (interleukin-1 beta [IL-I~], platelet-derived growth factor-AA 
[PDGF-AA], basic fibroblast growth factor [bFGF], interferon gamma [INFT], and tumor 
necrosis factor alpha [TNF-c~]) during the development of IH in a rat vein graft model. 
Methods: Rat epigastrie vein interposition grafts in the femoral artery were harvested at 6 
hours, 2 days, i week, 2 weeks, and 4 weeks after the grafting procedure and studied with 
immunohistochemical and standard histologic techniques. The cytokine xpression i the 
endothelium and media/neointima w s quantified as the percentage of immunopositive 
cells per high-power field. 
Results: Maximal hyperplasia occurred 2 weeks after the grafting procedure. Peak 
expression of IL-113 and bFGF occurred by 2 days. PDGF-AA expression paralleled the 
development of IH, peaking at 2 weeks and then declining. TNF-{x expression i creased at 
1 week and remained elevated. INF,/was seen only in control grafts. 
Conclusions: The coordinated early release of IL- 113 and bFGF and the down-regulation f 
I1NF~ seem to trigger an inflammatory esponse, thereby initiating IH. The process then is 
propagated by the release of PDGF-AA and TNF-a, with concomitant smooth muscle cell 
proliferation and production of extracellular matrix. It is likely that this complex milieu of 
local paracrine signaling is required to generate the hyperplastic response seen in failing 
vein grafts. (J Vase Surg 1996;24:463~71.) 
Autologous vein is used extensively in peripheral 
arterial and cardiac bypass urgery. ~'2 The success of 
these bypass grafts may be compromised by the 
development of intimal hyperplasia (IH) vein graft 
stenoses. 3,4 IH  accounts for 30% to 50% of bypass 
graft failures, s Although the cellular and molecular 
mechanisms that lead to the formation of IH  lesions 
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have not been clearly defined, evidence suggests that 
they may result from a pathologic response to vein 
graft arterialization. 6 Smooth muscle cell (SMC) 
migration and proliferation are pivotal events in the 
development of IH,  with the excess production of 
extracellular matrix molecules contributing to the 
mature lesionY -9 The development of IH is marked 
by a significant inflammatory infiltrate, with cells of 
monocyte lineage being the most abundant. ~°'n The 
inflammatory esponse isespecially prominent during 
the early stages of IH  lesion formation. ~2 These 
observations have led to the "response to injury" 
hypothesis, in which the proliferative changes een in 
IH are thought o result from an exaggerated wound- 
healing response to ar terialization.13'~4 In this hypoth- 
esis, cytoldnes and growth factors act as autocrine and 
paracrine signals to mediate chemotaxis, prolifera- 
tion, and extracellular matrix production. 15 
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Cytokine signaling has been studied during nor- 
real wound-healing responses in several tissues. 16 In 
these models a complex, coordinated cascade of 
paracrine and autocrine mediators is produced by 
inflammatory cells, SMCs, and fibroblasts. Similar 
cytokines and growth factors also have been impli- 
cated in the SMC hyperplastic response, as well as in 
the development of atherosclerotic plaques. The 
principal cytoldnes that are involved in the acute 
events within the vessel wall include the primary 
mediators of inflammation (tumor necrosis factor 
alpha [TNF-a] and interleuldn-1 beta [IL-I[~]), 
growt h factors that exhibit potent effects on SMCs 
(platelet-derived growth factor-AA [PDGF-AA] and 
basic fibroblast growth Factor [bFGF]), and a modu- 
lator of the immune response, interferon gamma 
(INFv). 
This study applics a rat model of vein graft IH 
healing that produced consistent hyperplastic lesions 
over a 4-week time coursc to study the expression of 
cytoldnes that have been implicated in the formation 
of lH.  17 
MATERIALS AND METHODS 
Microsurgical grafting procedure. Thirty-five 
Sprague-Dawlcy rats weighing between 325 and 400 
gm were used. All rats were treated in accordance with 
the "Principles of Laboratory Animal Care" (formu- 
lated by the National Society for Medical Research) 
and the Guide for the Care and Use of Laboratory 
Animals (NIH Publication No. 86 -23, revised 1985 ). 
Each rat was anesthetized by an intraperitoneal injec- 
tion of 40 mg/kg sodium pentobarbital. Using mi- 
crosurgical techniques under 10x magnification, the 
superficial epigastric vein and common femoral artery 
were dissected from the surrounding tissues (Fig. 1). 
An 8-mm long segment ofepigastric vein was excised 
and irrigated with 2 ml heparinized saline solution. A 
5-ram segment of the femoral artery then was re- 
sected, and the divided ends of the artery were 
irrigated with heparinized saline solution. The epigas- 
tric vein then was interposed into the arterial defect 
and sutured end-to-end to the femoral artery (Fig. 1, 
inset). Eight interrupted 10-0 Dermalon microsu- 
tures (Davis & Geck, Danbury, Conn.) were used for 
each anastomosis. Arterial occlusion time ranged 
from 45 minutes to 1 hour. When the arterial occlu- 
sion clamps were removed, immediate restoration of 
blood flow was confirmed. Patency was ensured by 
visual inspection and standard microsurgical tech- 
niques. 18 
Harvest. Six rats were killed at each of five time 
points: 6 hours, 2 days, I week, 2 weeks, and 4 weeks. 
After visual confirmation ofpatency, two grafts (one 
from each groin) with a 3-mm segment of proximal 
and distal artery were harvested from each rat. Eight 
grafts from each time point were prepared for immu- 
nohistochemical analysis. These grafts were perfused 
with OCT embedding compound (Tissue-Tek, 
Ell&ard, Ind.), snap-frozen in liquid nitrogen, and 
stored at -70 ° C. Two grafts from each time point, 
which were harvested for morphometric and histo- 
logic analyses, were perfusion-fixed at100 mm Hg in 
3% glutaraldehyde buffered to pH 7.4 with sodium 
cacodylate. Control superficial epigastric vein spcci- 
mens obtained from five rats that had not undcrgone 
graft insertion were harvested and processed in the 
manner described above. 
I-Iistologie and morphometrie analyses. The 
glutaraldehyde-fixed vessels were postfixed in 1% 
osmium tetroxide and dchydrated in increasing con- 
centrations of ethyl alcohol. Tissue samples were 
infiltrated with propylene oxide and flat-embedded in 
Epon 812. After polymerization, 1-gin sections of 
each specimen were cut longitudinally and stained 
with 1% azure II and methylene blue. 
Vein graft total-wall and intimal thickness were 
measured in the 1-pro sections and analyzed with a 
computer-digitized morphometric system (Bioscan 
Optimas, Edmon, Wash.). Measurements were made 
in the perianastomotic region and in the body of each 
graft at a site 3 mm from the anastomosis. 
Immunohistochemistry. Five-pro sections of 
each graft specimen were cut longitudinally on a 
Tissue-Tek cryostat, thaw-mounted on poly-L-ly- 
sine-coated glass slides, and air dried for 10 minutes. 
Tissue sections were fixed in 95% ethanol for 10 
minutes before antibody labeling. Endogenous per- 
oxidase activity was quenched with 1% (volume in 
volume; v/v) H202 in methanol for 20 minutes, and 
sections were washed in phosphate-buffered saline 
(PBS; Sigma Chemical, St. Louis). Nonspecific im- 
munoglobulin binding was blocked with appropriate 
2% (v/v) normal serum (goat, horse [Vector Labora- 
tories, Burlingame, Calif.]) in PBS. The tissue sec- 
tions were incubated with primary antibody for 45 
minutes at room temperature (25 ° C). They then 
were washed in PBS and incubated with biotinylated 
secondary antibody for 30 minutes. The sections were 
washed again in PBS and incubated for 30 minutes 
with an avidin-biotin complex reagent containing 
horseradish-peroxidase (V ctor Laboratories). After 
washing, the color was developed by incubation with 
a solution containing 0.5 mg/ml 3,3"-diaminobenzi- 
dine (DAB; Sigma Chemical) and 0.1% (v/v) H202 
for 20 minutes. The sections then were washed in 
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Fig. 1. Schematic representation of vein graft model preparation a d microsurgical technique. 
Inguinal fat pad is exposed and superficial epigastric vein is dissected free from surrounding tissue. 
Femoral vessels are isolated in preparation for grafting. Procedure is performed bilaterally ineach 
rat. Inset, Superficial epigastric vein is interposition grafted to femoral artery in end-to-end 
fashion. 
sterile, distilled water, and the color was darkened by 
incubation with 0.5% cupric sulfate for 5 minutes. 
Sections were counterstained with hematoxylin. For 
fiuorescein isothiocyanate (FITC)-conjugated anti- 
bodies, initial fixation in 95% ethanol was followed by 
blocking of nonspecific labeling with 2% normal 
serum. The tissue sections then were incubated with 
the FITC-conjugated primary antibody for 60 min- 
utes at room temperature (25 ° C) in the dark. The 
positive control tissues were TNF-c~, rat spleen and 
human atherosclerotic artery; bFGF, rat spleen and 
rat brain; IL-ll], rat spleen and human atherosclerotic 
artery; PDGF-AA, rat spleen, human atherosclerotic 
artery, and human platelets; INFy, rat spleen and 
injured rat spinal cord; proliferating cell nuclear 
antigen (PC10) proliferating rat SMC in culture; 
c~-actin, rat aorta; rat macrophage/monocyte, rat 
spleen. An absorption control was performed for each 
cytoldne at each of the time points with the synthetic 
peptide used for immunizations (1: 1 mix of antise- 
rum with 1 mg/ml solution of peptide). A negative 
control analysis was performed by replacing the 
primary" antibody with appropriate normal serum. 
Antibodies. The antibodies used were polyclonal 
rabbit antimouse TNF-c~ (IP-400, Genzyme, Cam- 
bridge, Mass.), 1:200 (v/v); polyclonal rabbit antirat 
IL-113 (124, Cytoldne Sciences, Boston), 1:20 (v/v); 
polyclonal rabbit antihuman PDGF-AA (ZP-214; 
Genzyrne), 1 : 100 (v/v); monoclonal mouse antibo- 
vine bFGF (05-118, Upstate Biotechnology, Lal;e 
Placid, N.Y.), 1 : 50 (v/v); monoclonal mouse antirat 
INFy (DB-1, AB-53-010, Biosource International, 
Camarillo, Calif.), 1:10 (v/v); monoclonal mouse 
anti-cz-SMC actin HTC-conjugate (1A4, Sigma 
Chemical), 1:400 (v/v); polyclonal rabbit antirat 
macrophage FITC-conjugate (AI-FAD51240, Accu- 
rate Chemical & Scientific, Westbury, N.Y.), 1:4 
(v/v); monoclonal mouse antiproliferating cell 
nuclear antigen, clone PC10 (1486 772, Boehringer 
Mannheim, Indianapolis, Ind.), 1:20 (v/v); biotiny- 
lated polyclonal goat antirabbit IgG (H + L) (BA- 
1000, Vector Laboratories), 1:100 (v/v); biotiny- 
lated horse antimouse IgG (H + L) (BA-2001,Vector 
Laboratories), 1:100 (v/v). 
Absorption control peptides. The absorption 
control peptides used were recombinant mouse 
TNF-c~ (TNF-M, Genzyme); recombinant rat IL-I~ 
(SPO 123, Cytoldne Sciences); recombinant human 
PDGF-AA homodimer (1695-01, Genzyme); bovine 
bFGF (f-5392, Sigma Chemical); recombinant rat 
INF 7 (CY-52-105, Biosource International). 
Quantitation of immunopositive c lls. Immu- 
nopositive cells were quantified as the percentage of
all cells, including cells of the vein graft wall and 
infiltrating inflammatory cells, that stained specifically 
for the cytokine being studied. Quantification was 
made for the endothelium and the neointima/media 
(Fig. 2). Separate determinations were made for the 
perianastomotic and midgraft regions. Four represen- 
tative areas of the midgraff region at four quadrants 
were examined under high power (400×) for each 
specimen. Four regions were examined at each peri- 
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Fig. 2. Cytokine xpression quantified as percentage ofimmunopositive c lls per high-power 
field in (A) neointima/media and (B) endothelium. 
anastomotic region again at four quadrants under 
high power (400×). Grafts from four rats were exam- 
ined at each of the time points for each of the five 
cytokines (TNF-ct, IL-1~3, PDGF-AA, bFGF, INF,/), 
the 0c-SMC actin, and the rat macrophage marker. 
The number ofimmunopositive cells was counted and 
recorded as the percentage ofthe total cells that were 
counted in each high-power field. The numbers from 
each high-power field then were pooled for analysis. 
No significant difference in cytokine expression was 
observed between the perianastomotic and midgraft 
regions, and these data were ultimately pooled to 
determine the mean level of expression of each 
cytokine at each time point. The histologist who 
evaluated the specimens was blinded to the region 
from which they were obtained. 
Statistical analysis. Data analysis was performed 
with Student's t test. Statistical significance was as- 
sumed at the 95% confidence level (p < 0.05). Data 
are represented asthe mean plus or minus standard 
deviation. 
RESULTS 
Histologic and morphometric analyses 
Disruption of the endothelium and rudimentary 
internal elastic laminae compared with ungrafted 
epigastric vein controls was observed as early as 6 
hours after the grafting procedure. Intramural hem- 
orrhage was noted, and the SMCs were spindle- 
shaped in appearance. Intimal thiclca~ess (perianasto- 
motic, 6 -+ 1 gm; midgraft, 4 _+ 1 gm) was not signifi- 
cantly different from control vein (p < 0.05). By 2 
days, inflammatory cells had infiltrated the subendo- 
thelial layers. Extracellular matrix components had 
increased in both regions of the graft. Total-wall 
thickness increased correspondingly (perianasto- 
motic, 141 + 16 gm; midgraft, 61 _ 26 gm), whereas 
intimal thiclmess again showed no significant increase 
over the control vein (p < 0.05). Significant endo- 
thelial denudation was present at 2 days and at 1 week. 
By 1 week after the grafting procedure, significantly 
more spindle-shaped SMCs were present; the extra- 
cellular matrix components of the media and neoin- 
tima also increased. Inflammatory cell infiltrates per- 
sisted within the media and neointima. Significant 
increases were observed inthe perianastomotic region 
both in the total-wall thickness (379+_14 gm; 
p = 0.002) and in the intimal thickness (27 _+ 2 gm; 
p = 0.003). No significant variation occurred in the 
pcrianastomotic hickness after 1 week (p > 0.05). In 
the midgraft region, total-wall and intimal thickness 
increased at 1 week, but they did not attain statistical 
significance tmtil 2 weeks (total-wall thickness, 
212+_61 gm; intimal thickness, 12_+ 1 gm; 
p = 0.04). Inflammatory cells declined after 2 weeks, 
and reorganization of the vein graft wall was ob- 
served. 
Cytokines and growth factors 
Data for the five cytokines tudied (TNF-cq IL- 
l J3, PDGF-AA, bFGF, and INFT) are summarized in
Fig. 3. Data from the perianastomotic and midgraft 
regions were compared and no statistical difference 
was found (p > 0.05). 
TNF-c~. Initial TNF-~ expression was low 
in both the media/neointima (14%_+8%) and 
the endothelium (10%+- 12%) and remained un- 
changed until 1 week, when it increased ramatically 
(media/neointima, 84% +- 7%, p -- 0.001; endothe- 
lium, 73% _+ 21%, p = 0.03). TNF-a levels remained 
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Fig. 3. Immunohistochemical an lysis of PDGF-AA pro- 
tein in intimal hyperplasia 2 weeks after grafting procedure. 
A, Diffuse immunostaining throughout neointima/media 
is seen (100x). B, At higher magnification, predominant 
cytoplasmic staining pattern (ar ow) is evident (400x). C,
Absorption control (HRP/DAB, hematoxylin). 
elevated at 2 weeks (media/neointima, 95% + 2%; 
endothelium, 94%+ 6%, p=0.001) and 4 weeks 
(media/neointima, 95% ± 3%; endothelium, 83% + 
14%). 
IL-I~. IL-I~ expression increased rapidly from 
low baseline levels (media/neointima, 18% + 12%; 
endothelium, 17% ± 13%) to peak at 6 hours in the 
endothelium (68% ± 16%, p = 0.04) and at 2 days in 
the media/neointima (71% _+ 16%, p = 0.03; Fig. 4). 
By 1 week IL-l[3 expression had decreased to below 
baseline levels (media/neointima 18% ± 12%; endo- 
thelium, 17% ± 19%). 
Fig. 4. Immunohistochemical analysis oflL-l[3 protein in 
intimal hyperplasia at 6 hours. (A, IL-II]; B, absorption 
control; HRP/DAB 400x). Arrow indicates typical granu- 
lar staining pattern ofmacrophage IL-l[3 expression. 
PDGF-AA. The time course of PDGF-AA ex- 
pression in the neointima/media p ralleled that of 
proliferating cell nuclear antigen expression and cor- 
relatcd well with the development of significant 
neointimal/medial thickening. Low baseline xpres- 
sion in the neointima/media (16% +_ 10%) persisted 
until 1 week (73% _ 20%, p = 0.03; Fig. 3). A tran- 
sient increase in PDGF-AA expression within the 
endothelium was observed at 6 hours (40% +_ 12%), 
which resolved at 2 days (5% + 10%) and increased 
again at 1 week (63% +_ 8%, p = 0.01). Expression in 
both the media/neointima and the endothelium 
remained elevated at 2 weeks (media/neointima, 
68% ± 1I%; endothelium, 42% __ i7%) and returned 
to near baseline levels by 4 weeks (media/neointima, 
31% ± 15%; endothelium, 18% ± 8%). 
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Fig. 6. Immunohistochemical analysis of INFy protein in 
control vein. A, Control epigastric vein demonstrates ig- 
nificant neointimal/medial expression of INFy protein 
(100x) (arrows). After grafting procedure, no INFy expres- 
sion is present. B, Absorption control (HRP/DAB, hema- 
toxylin). 
Fig. 5. Immunohistochemical an ysis ofbFGF protein in 
intimal hyperplasia 2 days after grafting procedure. A, 
Intense subendothelial distribution of bFGF is seen (ar- 
rows). Sporadic neointimal/medial staining is also present 
(100x). B, Absorption control (HRP/DAB, hematoxylin). 
bFGB. bFGF demonstrated a bimodal pattern of 
expression i the media/neointima and the endothe- 
lium. The first peak in expression occurred at 2 days 
after the grafting procedure (media/neointima, 
68% ± 16%, p= 0.02; endothclium, 73% ± 21%, 
p = 0.01), with a return to near baseline levels at 1 
week (media/neointima, 21%±9%; endothelium, 
29% ± 17%). The second, smaller peak in expression 
occurred at 2 weeks (media/neointima, 46% _ 24%; 
endothelium, 57% ± 17%; Fig. 5) and decreased by 4 
weeks (media/neointima, 12% ± 13%; endothelium, 
9% ± 10%). 
INFy. Significant levels of INFy expression were 
present in the media of ungrafted epigastric vein 
specimens (43% ± 7%; Fig. 6). The level of INFy 
expression decreased to near 0 by 6 hours (2% _+ 1%, 
p < 0.001) and remained there. 
Macrophage/monocyte, c~-SMC act±n, and 
PC10. Cells that labeled positive for ~-SMC actin 
were the predominant cell type at all time points (46% 
to 79%; Fig. 7). Those cells that labeled positive with 
Fig. 7. Immunohistochemical analysis of ~-SMC actin 
protein in intimal hyperplasia 1 week after grafting proce- 
dure. Immunostaining-identified smooth muscle cells are 
limited to neointima/media (100x) (FITC-anti-~-SMC 
act±n). 
the rat macrophage antibody comprised a significant 
minority of cells, with maximum expression at 1 week 
(21%). PC10 expression did not increase significantly 
until 1 week after the grafting procedure and rapidly 
declined thereafter (perianastomotic, 6 hours: 
13% _ 7%, 2 days: 23% _+14%, 1 week: 70% ± 20%, 2 
weeks: 47% _+ 17%, 4 weeks: 17% ± 11%; midgraft, 6 
hours: 11%+8%, 2 days: 19%±11%, 1 week: 
63% ± 12%, 2 weeks: 41% ± 7%, 4 weeks: 8% ± 6%). 
DISCUSSION 
Despite the success of autologous vein grafts in 
arterial reconstruction, IH remains aleading cause of 
JOURNAL OF VASCULAR SURGERY 
Volume 24, Number 3 Faries et aL 469 
graft failure. Although the cause of IH remains 
elusive, a prominent role has been established for 
SMCs in the pathogenesis ofIH.19,2° SMC migration 
and proliferation and extracellular matrix accumula- 
tion occur during IH lesion development, possibly as 
a response to vein graft injury after arterialization. 6'21 
A coordinated cascade of events that involve the 
differential expression of cellular growth regulators i
necessary to produce the hyperplastic response in the 
intima of vein grafts) sPart of this regulating process 
has been described, including the events associated 
with endothelial cell injury, recruitment of inflamma- 
tory cells, 1° and platelet aggregation and degranula- 
tion.14 Examples of isolated growth factor or cytokine 
expression in vitro also have been described) 2,1~,22 
However, because the interaction between cytokines 
in vivo may be additive or inhibitory, the extrapola- 
tion of the activity of an individual cytokine to an 
entire pathophysiologic system isdifficult. To date, no 
comprehensive localization or quantification of the 
protein signals that occur during IH formation has 
been described. 
TNF-c~ has been demonstrated to be a principal 
mediator of both the systemic and the local responses 
to injury, z3'24 It is responsible for a wide range of 
physiologic effects, including stimulation of the im- 
mune response. 25TNF-c~ effects een in leukocytes 
are often affected by the presence of additional 
cytoldnes, particularly INF7 and IL-I[3. 26 TNF-o~ 
promotes vascular SMC proliferation i  cell culture 27 
and is produced both by SMCs and by endothelial 
cells in atherosclerotic arteries. 28,29 Our data demon- 
strate a dramatic increase in TNF-c~ expression i the 
hyperplastic vein grafts 1 week after the grafting 
procedure. This increase correlated with the peal~ in 
cell proliferation that occurred at 1 week. TNF-c~ 
expression remained elevated at 2 weeks after the 
grafting procedure, when additional increases in inti- 
real thickaaess and total-wall thickness were observed. 
Significant remodeling occurred 4 weeks after the 
grafting procedure when elevated TNF-c~ expression 
persisted. It appears that the TNF-a effects in our 
model o f lH  are influenced by the relative xpression 
of other cytokines. The role of TNF-o~ appears to be 
complex and multifaceted, involving cellular prolif- 
eration, extracellular matrix production, and remod- 
eling. 
IL-I~, acts as a paracrine and autocfine signal in 
the inflammatory response that is seen in acute 
injury 3° and wound healing. 16 In these situations, 
IL-113 expression is rapidly induced and serves to 
promote leukocyte infiltration 3°m and extracellular 
matrix degradation. 32'33 IL-I~ is produced in the 
arterial wall, 34 where it has been shown to activate 
leukocytes and other cellular components. 1~,=,35 It
may stimulate SMCs and endothelial cells to express 
additional cytoldnes and growth factors) ~,22,a5 The 
peak expression of IL- 1 [5 occurred within 6 hours of 
the grafting procedure, which supports a role for 
IL-1I] in the acute response to arterialization. The 
early expression ofIL- 1 [3 may induce further cytoldne 
expression and promote the series of reactions that are 
necessary toproduce IH. The return ofIL-1 [3 expres- 
sion to the baseline levels by i week after the grafting 
procedure suggests that its most prominent effects 
may be related to the induction of the SMC hyper- 
plastic response and that the effects of this molecule 
are limited beyond the initial phases of leukocyte and 
SMC migration and activation. 
A variety of effects have been attributed to 
PDGF-AA in the development ofvein graft IH and 
atherosclerosis. PDGF-AA is produced by vascular 
SMCs and has been demonstrated to be an important 
regulator of vascular SMC replication and migra- 
l ion.  a6 Macrophages and epithelial cells also are ca- 
pable of producing PDGF-AA. PDGF-AA has been 
isolated from human atherosclerotic arterial speci- 
mens and has been localized by in situ hybridization to 
the diseased intimal portion of these vesselsS 
PDGF-AA production correlates with the IH pro- 
duced after balloon-induced vascular injuries. 9 In 
addition, gene transfer of an expression vector plas- 
mid that encodes PDGF into porcine iliofemoral 
arteries results in significant neointimal thickening in 
these vessels. 3s PDGF-AA has been implicated in the 
development ofIH in human polytetrafluoroethylene 
grafts, a9 In our study, PDGF-AA expression by vas- 
cular SMCs closely paralleled the development ofIH. 
PDGF-AA expression peaked at 1 week, which cor- 
responded with maximal proliferation as measured by 
PC10. PDGF-AA expression remained significantly 
elevated at 2 weeks, when the intima reached its 
maximum thickness. The decline in proliferation and 
remodeling of the vessel wall observed at 4 weeks 
corresponded with a return to baseline levels of 
PDGF-AA expression. These observations support a 
role for P.DGF-AA in SMC proliferation and migra- 
tion and suggest astimulatory effect on extracellular 
matrix production. 
Endogenous bFGF, which is released from vascu- 
lar tissues after injury, has been shown to promote 
vascular SMC migration and proliferation within the 
injured region. 4°-42 The addition of bFGF after ex- 
perimentally induced balloon injury of rabbit aortas 
resulted in acceleration of the preliminary phases of 
IH development) 3'44 Furthermore, the administra- 
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tion of exogenous anti-bFGF after aortic balloon 
injury in rabbits resulted in significant IH inhibi- 
tion. 4s'46 A similar inhibition of IH formation in 
balloon-injured rat carotid arteries also was achieved 
by the addition of anti-bFGF antibody. 4s These ob- 
servations suggest that bFGF plays a complex role in 
the development of vascular hyperplastic lesions, 
involving both the induction and the promotion of 
lesion formation. In our model of IH formation, we 
have shown that bFGF expression is bimodal. The first 
increase in expression peaked by 2 days after the 
grafting procedure and regressed by 1 week. During 
this time, macrophages infiltrated the vessel wall and 
SMCs were seen in increasing numbers. A second 
increase in bFGF expression occurred at 2 weeks, 
when the hyperplastic lesions reached their maximal 
thickness. The role ofbFGF appears to be influenced 
by the presence of additional cytokines in the local 
signaling milieu. When it is combined with IL-113, 
inflammation results, whereas in the presence of 
PDGF-AA and TNF-~, bFGF promotes SMC and 
extracellular matrix accumulation. 
IND/exhibits a variety of effects on leukocyte 
cytoldne production. 47 The clown-regulation f lNFy 
expression that is seen in the vein after the grafting 
procedure in our model suggests that a relative 
absence of IND[ may be necessary to permit the 
development of IH. Such a permissive down-regula- 
tion that results in IH is supported by the previous 
observations of human vascular SMC growth inhibi- 
tion by INF 7 in cell culture 27 and the inhibition of 
stenotic lesion formation after arterial injury in rat 
carotid artery balloon catheter-induced injury. INF7 
may be an inhibitory factor in the formation of IH 
lesions. 
The formation of IH lesions in vein bypass grafts 
is the result of numerous cellular events, including 
leulmcyte infiltration and activation, SMC migration 
and proliferation, and extracellular matrix production 
and deposition. A coordinated cascade of intercellular 
signaling is necessary to produce the events that result 
in IH. We used a rat model of SMC proliferation and 
intimal thickening to describe the temporal sequence 
and distribution of expression of five cytokines that 
significantly influence cellular development. We cor- 
related these results with the observed proliferation 
and inflammatory cell infiltration. Our results upport 
the hypothesis that coordinated paracrine and auto- 
crine signaling by cytokines is responsible for the 
generation of IH. These results may provide a target 
for therapy, with intervention early in the time course 
of IH  development directed at reducing IL-1 ~ pro- 
duction. Blocldng oflL- 113 may prevent the initiation 
of the cytokine cascade. Interventions directed at the 
mediators of the subsequent events in IH  develop- 
ment, such as bFGF and PDGF, with neutralizing 
antibodies or direct antisense gene transfer, also may 
be effective in reducing the hyperplastic response. 
Up-regulation of INF 7 production in vein grafts 
could be attempted todecrease or reverse hyperplasia. 
Further study of these interventions in models o f lH  
is the next logical step in attempting to identify 
treatment methods to prevent IH lesion formation 
and so provide improved long-term bypass graft 
patency and function. 
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